166 related articles for article (PubMed ID: 29494150)
1. Circulating Microvesicles from Pancreatic Cancer Accelerate the Migration and Proliferation of PANC-1 Cells.
An M; Zhu J; Wu J; Cuneo KC; Lubman DM
J Proteome Res; 2018 Apr; 17(4):1690-1699. PubMed ID: 29494150
[TBL] [Abstract][Full Text] [Related]
2. Effects of ER-resident and secreted AGR2 on cell proliferation, migration, invasion, and survival in PANC-1 pancreatic cancer cells.
Hong X; Li ZX; Hou J; Zhang HY; Zhang CY; Zhang J; Sun H; Pang LH; Wang T; Deng ZH
BMC Cancer; 2021 Jan; 21(1):33. PubMed ID: 33413231
[TBL] [Abstract][Full Text] [Related]
3. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
[TBL] [Abstract][Full Text] [Related]
4. CD133(+)/CD44(+)/Oct4(+)/Nestin(+) stem-like cells isolated from Panc-1 cell line may contribute to multi-resistance and metastasis of pancreatic cancer.
Wang D; Zhu H; Zhu Y; Liu Y; Shen H; Yin R; Zhang Z; Su Z
Acta Histochem; 2013 May; 115(4):349-56. PubMed ID: 23036582
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs).
Wang L; Zhang Y; Wang W; Zhu Y; Chen Y; Tian B
PLoS One; 2017; 12(8):e0184110. PubMed ID: 28854261
[TBL] [Abstract][Full Text] [Related]
6. Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
Tang ZY; Wu YL; Gao SL; Shen HW
J Surg Res; 2008 Mar; 145(1):111-23. PubMed ID: 17714734
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine Induces Microvesicle Particle Release in a Platelet-Activating Factor-Receptor-Dependent Manner via Modulation of the MAPK Pathway in Pancreatic Cancer Cells.
Thyagarajan A; Kadam SM; Liu L; Kelly LE; Rapp CM; Chen Y; Sahu RP
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577630
[TBL] [Abstract][Full Text] [Related]
8. Hyperthermia inhibits the motility of gemcitabine-resistant pancreatic cancer PANC-1 cells through the inhibition of epithelial-mesenchymal transition.
Jin H; Zhao Y; Zhang S; Yang J; Zhang X; Ma S
Mol Med Rep; 2018 May; 17(5):7274-7280. PubMed ID: 29568909
[TBL] [Abstract][Full Text] [Related]
9. Side population in the pancreatic cancer cell lines SW1990 and CFPAC-1 is enriched with cancer stem-like cells.
Yao J; Cai HH; Wei JS; An Y; Ji ZL; Lu ZP; Wu JL; Chen P; Jiang KR; Dai CC; Qian ZY; Xu ZK; Miao Y
Oncol Rep; 2010 May; 23(5):1375-82. PubMed ID: 20372854
[TBL] [Abstract][Full Text] [Related]
10. Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.
Ozaki T; Nakamura M; Ogata T; Sang M; Yoda H; Hiraoka K; Sang M; Shimozato O
Oncotarget; 2016 Nov; 7(44):71937-71950. PubMed ID: 27713122
[TBL] [Abstract][Full Text] [Related]
11. 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells.
Halloran CM; Ghaneh P; Shore S; Greenhalf W; Zumstein L; Wilson D; Neoptolemos JP; Costello E
J Gene Med; 2004 May; 6(5):514-25. PubMed ID: 15133762
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine inhibits proliferation and induces apoptosis in human pancreatic cancer PANC-1 cells.
Yong-Xian G; Xiao-Huan L; Fan Z; Guo-Fang T
J Cancer Res Ther; 2016 Oct; 12(Supplement):1-4. PubMed ID: 27721241
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.
Avan A; Quint K; Nicolini F; Funel N; Frampton AE; Maftouh M; Pelliccioni S; Schuurhuis GJ; Peters GJ; Giovannetti E
Curr Pharm Des; 2013; 19(5):940-50. PubMed ID: 22973962
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of Ezrin by RNA interference reverses malignant behavior of human pancreatic cancer cells in vitro.
Zhong ZQ; Song MM; He Y; Cheng S; Yuan HS
Asian Pac J Cancer Prev; 2012; 13(8):3781-9. PubMed ID: 23098471
[TBL] [Abstract][Full Text] [Related]
16. Aspirin inhibits proliferation of gemcitabine-resistant human pancreatic cancer cells and augments gemcitabine-induced cytotoxicity.
Ou YQ; Zhu Wb; Li Y; Qiu PX; Huang YJ; Xie J; He SM; Zheng XK; Leng TD; Xu D; Yan GM
Acta Pharmacol Sin; 2010 Jan; 31(1):73-80. PubMed ID: 19966835
[TBL] [Abstract][Full Text] [Related]
17. MiR-373-3p enhances the chemosensitivity of gemcitabine through cell cycle pathway by targeting CCND2 in pancreatic carcinoma cells.
Hu W; Liu Q; Pan J; Sui Z
Biomed Pharmacother; 2018 Sep; 105():887-898. PubMed ID: 30021382
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-200c overexpression inhibits chemoresistance, invasion and colony formation of human pancreatic cancer stem cells.
Ma C; Huang T; Ding YC; Yu W; Wang Q; Meng B; Luo SX
Int J Clin Exp Pathol; 2015; 8(6):6533-9. PubMed ID: 26261532
[TBL] [Abstract][Full Text] [Related]
19. Clobenpropit enhances anti-tumor effect of gemcitabine in pancreatic cancer.
Paik WH; Ryu JK; Jeong KS; Park JM; Song BJ; Lee SH; Kim YT; Yoon YB
World J Gastroenterol; 2014 Jul; 20(26):8545-57. PubMed ID: 25024609
[TBL] [Abstract][Full Text] [Related]
20. DNA-PKcs is important for Akt activation and gemcitabine resistance in PANC-1 pancreatic cancer cells.
Hu H; Gu Y; Qian Y; Hu B; Zhu C; Wang G; Li J
Biochem Biophys Res Commun; 2014 Sep; 452(1):106-11. PubMed ID: 25152407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
